Dr. Fagan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3190 N Swan Rd
Tucson, AZ 85712Phone+1 520-547-9700Fax+1 520-547-9719
Education & Training
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1973 - 1976
David Geffen School of Medicine at UCLAClass of 1973
Certifications & Licensure
AZ State Medical License 1981 - 2021
SC State Medical License 1976 - 1981
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013
Clinical Trials
- Carbidopa-levodopa in Neovascular AMD Start of enrollment: 2017 May 02
- Dose Ranging Study of Carbidopa-levodopa Start of enrollment: 2017 May 02
- Carbidopa-Levodopa in Dry AMD With Geographic Atrophy Start of enrollment: 2018 Jul 01
Publications & Presentations
PubMed
- 19 citationsLevodopa Positively Affects Neovascular Age-Related Macular Degeneration.Anna G. Figueroa, Brennan M. Boyd, Cory A. Christensen, Cameron G. Javid, Brian S. McKay
The American Journal of Medicine. 2021-01-01 - Payments to Physicians, Prescribing Rates, and More Appropriate ConclusionsTimothy C. Fagan
JAMA Internal Medicine. 2016-10-01 - 5 citationsPulse pressure responses in patients treated with Valsartan and hydrochlorothiazide combination therapy.Renzo Carretta, Peter Trenkwalder, F. Martinez, Andrzej Tykarski, I. Teitelbaum
The Journal of International Medical Research. 2003-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
